Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MAPK3 | P27361 | 13/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25531479 | 1.00 | TRPV1 (0.46) | TRPV1HDAC4HDAC6MAPK3BTK | |
| SCHEMBL31548557 | 0.95 | MAPK3 (0.48) | HDAC4HDAC6MAPK3BTKPTK2 | |
| SCHEMBL25596033 | 0.85 | TRPV1 (0.49) | TRPV1HDAC4HDAC6MAPK3BTK | |
| SCHEMBL15938357 | 0.84 | MAPK3 (0.51) | TRPV1HDAC4HDAC6MAPK3BTK | |
| SCHEMBL15938356 | 0.84 | MAPK3 (0.51) | TRPV1HDAC4HDAC6MAPK3BTK | |
| SCHEMBL30697139 | 0.83 | IDH1 (0.44) | HDAC4MAPK3PTK2IDH1 | |
| SCHEMBL31006774 | 0.83 | TRPV1 (0.42) | TRPV1MAPK3PTK2 | |
| SCHEMBL30397019 | 0.80 | ULK1 (0.43) | MAPK3PTK2 | |
| SCHEMBL24704507 | 0.78 | MAPK3 (0.52) | TRPV1HDAC4HDAC6MAPK3BTK | |
| SCHEMBL28543270 | 0.78 | MAPK3 (0.52) | TRPV1HDAC4HDAC6MAPK3BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023091726-A1 | INHIBITORS OF CYCLIN‑DEPENDENT KINASE 12 (CDK12) | SYROS PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |